Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Otsuka Calls Off PIII Bipolar Trial for SEP-4199 on Stalled Recruitment
November 1, 2023
- Daiichi Sankyo’s H1 Sales Jump 19.5% on Robust Global Products
November 1, 2023
- Idorsia Files Insomnia Med Daridorexant in Japan: Sosei, Mochida
November 1, 2023
- Shionogi Notches Record Earnings in April-September, Xocova Drives Growth
November 1, 2023
- 301 Employees Apply for Shionogi’s Voluntary Buyout Program
November 1, 2023
- VLP Therapeutics Eyes Japan Filing of Next-Gen mRNA Vaccine in Mid-2024: CEO
October 31, 2023
- BIKEN Files Updated Version of Measles-Rubella Vaccine Mearubik
October 31, 2023
- Hyftor Now Available in EU, UK: Nobelpharma
October 31, 2023
- Nippon Kayaku Gets Japan Commercial Rights to Anheart’s ROS1 Inhibitor
October 31, 2023
- Otsuka’s ADHD Med Hits Mark in PIII Pediatric Trials in US
October 30, 2023
- Sumitomo Awards AlphaNavi Worldwide Rights to Neuropathic Pain Therapy
October 27, 2023
- Takeda’s H1 Profit Tumbles on Write-Down Tied to Trial Setbacks, Outlook Slashed
October 27, 2023
- Merck Sues Sawai over Januvia Generics Approved in Japan
October 27, 2023
- Novartis Expects Limited Impact of siRNA Therapy in Drug Cost: Exec
October 26, 2023
- Yoshindo Recalls Some Nizatidine Products over Carcinogen Risks
October 26, 2023
- Japan Approves Spikevax for Primary Shots in Six Months and Above
October 26, 2023
- BMS Files Repotrectinib in Japan for ROS1-Positive NSCLC
October 26, 2023
- With Wholesalers Narrowed Down, Hospitals Face Squeezed Discounts for GSK Products
October 25, 2023
- Yakult to Divest Cancer Portfolio to Takata, Pull Plug on New Development
October 25, 2023
- Roche Group, Biogen Reach Settlement over Actemra Biosimilar
October 25, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…